You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(688180.SH/1877.HK):9月13-27日新冠中和抗體在美國共發放7.8萬劑

格隆匯9月23日丨君實生物(688180.SH/1877.HK)公佈近日,美國衞生與公共服務部HHS表示,由於Delta變異病毒與國家特定地區的低疫苗接種率導致了在2021年7月至8月期間,COVID-19病例數量增加,而且這段時間內COVID-19單克隆抗體療法(mAbs訂單量增加了20倍。

為應對這一需求的增加,負責準備和響應的助理部長HHS辦公室已於2021年9月13日過渡到使用能協調州和地方的mAbs分發系統。聯邦政府的首要任務是以高效、公平和公正的方式分配mAbs。不僅如此,州/地方的衞生部門清楚其轄區內的需求,能夠更好地確定產品的分發。

當地時間9月2日,美國FDA和ASPR(美國應急準備與反應助理部長辦公室)宣佈,恢復埃特司韋單抗(etesevimab,JS016)/巴尼韋單抗(bamlanivimab,LY-CoV555)在美國所有州、地區和司法管轄區的使用和分發。從君實/禮來新冠雙抗體療法在美國範圍內發放的劑量總數來看,9月13-20日發放17880劑,9月21-27日發放60208劑,合計共發放了78088劑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account